ValiRx PLC (VAL)

Industry Biotechnology

This stock can be held in an Investment ISA, SIPP and Investment Account

Sell

0.28p

Buy

0.30p

arrow-down-0.02p (-6.45%)

Prices updated at 17 Apr 2026, 15:20 BST

Prices minimum 15 mins delay

Prices in GBX

ValiRx PLC is a biopharmaceutical company. It is engaged in developing technologies and products in oncology therapeutics and diagnostics focused on the treatment of cancer and associated Biomarkers, specializing in epigenomic and genetic analysis.

FTSE All-Share

0.86%

LSE

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Biotechnology

Chairman

Mr. Martin John Gouldstone

CEO

Dr. Mark Edward Eccleston

Most recent earnings

31 Dec 2024

Fiscal year end

31 Dec 2024

Employees

14

Head office

D6 Thane Road

Nottingham

United Kingdom

NG90 6BH

+44 1157840026

info@valirx.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Mr. Martin John Gouldstone Non-Executive Director, Chairman	-
Ms. Catherine Jane Tralau-Stewart Non-Executive Director	-
Mr. Gerald Desler Executive Director, Chief Financial Officer and Company Secretary	-
Dr. Mark Edward Eccleston Executive Director, Chief Executive Officer	-

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
No data

Director dealings

Date chevron-l-regular chevron-r-regular	Action
03 Mar 2026	Purchase
21 Nov 2025	Purchase
21 Nov 2025	Purchase
21 Nov 2025	Purchase
21 Nov 2025	Purchase

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.